Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | SCN4A | P35499 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | PNLIP | P16233 | 1/20 | 0.46 |
| ▸ | TAAR5 | O14804 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | BAX | Q07812 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10664102 | 0.81 | TAAR5 (0.49) | HSPB1MEN1KMT2AESR1ESR2 | |
| SCHEMBL9762780 | 0.81 | MEN1 (0.45) | HSPB1MEN1KMT2AESR1ESR2 | |
| SCHEMBL10559362 | 0.81 | SCN9A (0.50) | MEN1KMT2AESR1ESR2 | |
| SCHEMBL4374841 | 0.81 | HSPB1 (0.58) | HSPB1MEN1KMT2ASCN4AAR | |
| SCHEMBL9339651 | 0.81 | HSPB1 (0.58) | HSPB1SCN4AARTRPA1 | |
| SCHEMBL4372913 | 0.81 | HSPB1 (0.58) | HSPB1SCN4AARPNLIPTRPA1 | |
| SCHEMBL18646614 | 0.81 | HSPB1 (0.58) | HSPB1MEN1KMT2ASCN4AAR | |
| SCHEMBL8298015 | 0.81 | HSPB1 (0.58) | HSPB1SCN4AARTRPA1 | |
| SCHEMBL15331685 | 0.80 | HSPB1 (0.54) | HSPB1SCN4AARPNLIPTRPA1 | |
| SCHEMBL4046853 | 0.80 | PARP10 (0.61) | MEN1KMT2AESR1ESR2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0363308-A1 | Ethers | CIBA-GEIGY AG (CH) | 1990-04-11 | — | — | EP | claimed |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| EP-3060550-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-05-15 | — | — | EP | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| EP-3060550-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061247-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-04-30 | — | — | WO | disclosed |
| EP-0363308-B1 | Ethers | CIBA GEIGY AG (CH) | 1994-06-01 | — | — | EP | disclosed |
| US-5229426-A | Treating with 1-(4-(halophenoxy)-phenoxy)-4-pentyne | CIBA-GEIGY CORPORATION (US) | 1993-07-20 | — | — | US | disclosed |
| US-5114977-A | Ovicidal control of pests | CIBA-GEIGY CORPORATION (US) | 1992-05-19 | — | — | US | disclosed |
| EP-0363308-A1 | Ethers | CIBA-GEIGY AG (CH) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | HSPB1 2931/4885MEN1 4112/4885KMT2A 1229/4885 |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | HSPB1 2931/4885MEN1 4112/4885KMT2A 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.